CAR T-Cell Therapy clinical trials at UCSF

2 research studies open to eligible people

Showing trials for

  • CAR-T Long Term Follow Up (LTFU) Study

    open to all eligible people

    Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all patients exposed to CAR-T therapied for 15 years following their last CAR-T (e.g. CTL019) infusion to assess the risk of delayed adverse events (AEs), monitor for replication competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.

    San Francisco, California and other locations

  • MM CAR-T to Upgrade Response BMTCTN1902

    open to eligible people ages 18-71

    This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).

    San Francisco, California and other locations

Last updated: